Skip to main content
BMRN
NASDAQ Life Sciences

BioMarin 终止多个 Voxzogo 2期试验，理由是不良事件

feedReported by Reuters
Sentiment info
Negative
Importance info
7
Price
$57.5
Mkt Cap
$11.253B
52W Low
$50.76
52W High
$73.18
Market data snapshot near publication time

summarizeSummary

BioMarin 制药公司宣布终止其针对特纳综合征、SHOX缺陷和ACAN缺陷的Voxzogo 2期试验。这一决定是在两个正在进行的调查者赞助试验中观察到多个股骨头上髁滑脱事件之后做出的。虽然Voxzogo仍然获得了软骨发育不全和其他2期试验的批准，例如诺恩综合征和特发性矮小症试验将继续进行，但这一举动显著地削减了该药物扩大到这些额外适应症的潜在市场。即使这些不良事件特定于这些患者人群，也会引入负面的临床数据点，并降低公司未来的收入增长潜力。投资者现在将关注剩余Voxzogo试验的进展和安全性特征。

在该公告发布时，BMRN的交易价格为$57.50，交易所为NASDAQ，所属行业为Life Sciences，市值约为$112.5亿。 52周交易区间为$50.76至$73.18。 这则新闻被评估为消极市场情绪，重要性评分为7/10。 来源：Reuters。

show_chartPrice Chart

Share this article

Copied!

feed BMRN - Latest Insights

BMRN
Apr 27, 2026, 8:45 AM EDT
Filing Type: 8-K
Importance Score:
9
BioMarin Finalizes $4.8 Billion Acquisition of Amicus Therapeutics, Secures $3.4 Billion in New Debt
Sentiment: Neutral
View Wiseek Article
BMRN
Apr 27, 2026, 8:44 AM EDT
Source: Dow Jones Newswires
Importance Score:
7
BioMarin Officially Closes Amicus Therapeutics Acquisition
Sentiment: Neutral
View Wiseek Article
BMRN
Apr 23, 2026, 4:23 PM EDT
Source: Wiseek News
Importance Score:
8
BioMarin Clears Final French FDI Hurdle for Amicus Merger, Deal Expected to Close April 27
Sentiment: Positive
View Wiseek Article
BMRN
Apr 23, 2026, 4:20 PM EDT
Filing Type: 8-K
Importance Score:
8
BioMarin Secures Final French FDI Clearance for Amicus Therapeutics Merger, Closing Expected April 27
Sentiment: Positive
View Wiseek Article
BMRN
Apr 21, 2026, 4:19 PM EDT
Filing Type: DEF 14A
Importance Score:
8
BioMarin Seeks Shareholder Approval for Significant Equity Plan Expansion and Board Leadership Transition
Sentiment: Negative
View Wiseek Article
BMRN
Mar 16, 2026, 8:38 AM EDT
Source: Reuters
Importance Score:
7
BioMarin Discontinues Multiple Voxzogo Phase 2 Trials Citing Adverse Events
Sentiment: Negative
View Wiseek Article
BMRN
Mar 16, 2026, 8:30 AM EDT
Filing Type: 8-K
Importance Score:
8
BioMarin Halts VOXZOGO Phase 2 Trials for Multiple Indications Due to Safety Concerns
Sentiment: Negative
View Wiseek Article
BMRN
Feb 27, 2026, 8:02 PM EST
Source: Reuters
Importance Score:
7
FDA Expands BioMarin's Palynziq Approval to Adolescents with PKU
Sentiment: Positive
View Wiseek Article
BMRN
Feb 26, 2026, 12:30 PM EST
Filing Type: 10-K
Importance Score:
8
BioMarin Reports Full-Year 2025 Results, Details Amicus Acquisition, and ROCTAVIAN Withdrawal
Sentiment: Neutral
View Wiseek Article
BMRN
Feb 23, 2026, 4:08 PM EST
Filing Type: 8-K
Importance Score:
8
BioMarin Reports Mixed Q4/FY25 Results, Withdraws ROCTAVIAN, Issues Strong 2026 EPS Guidance
Sentiment: Neutral
View Wiseek Article